Developing drugs for developing countries.


Journal Article

Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.

Full Text

Duke Authors

Cited Authors

  • Ridley, DB; Grabowski, HG; Moe, JL

Published Date

  • March 2006

Published In

Volume / Issue

  • 25 / 2

Start / End Page

  • 313 - 324

PubMed ID

  • 16522573

Pubmed Central ID

  • 16522573

Electronic International Standard Serial Number (EISSN)

  • 1544-5208

International Standard Serial Number (ISSN)

  • 0278-2715

Digital Object Identifier (DOI)

  • 10.1377/hlthaff.25.2.313


  • eng